Corley D A, Kubo A, Levin T R, Block G, Habel L, Zhao W, Leighton P, Rumore G, Quesenberry C, Buffler P, Parsonnet J
Division of Research, Kaiser Permanente, 2000 Broadway, Oakland, CA 94612, USA.
Gut. 2008 Jun;57(6):727-33. doi: 10.1136/gut.2007.132068. Epub 2007 Sep 25.
Gastric colonisation with the Helicobacter pylori bacterium is a proposed protective factor against oesophageal adenocarcinoma, but its point of action is unknown. Its associations with Barrett's oesophagus, a metaplastic change that is a probable early event in the carcinogenesis of oesophageal adenocarcinoma, were evaluated
A case-control study was carried out in the Kaiser Permanente Northern California population, a large health services delivery organisation. Persons with a new Barrett's oesophagus diagnosis (cases) were matched to subjects with gastro-oesophageal reflux disease (GORD) without Barrett's oesophagus and to population controls. Subjects completed direct in-person interviews and antibody testing for H pylori and its CagA (cytotoxin-associated gene product A) protein.
Serological data were available on 318 Barrett's oesophagus cases, 312 GORD patients and 299 population controls. Patients with Barrett's oesophagus were substantially less likely to have antibodies for H pylori (OR = 0.42, 95% CI 0.26 to 0.70) than population controls; this inverse association was stronger among those with lower body mass indexes (BMIs < 25, OR = 0.03, 95% CI 0.00 to 0.20) and those with CagA+ strains (OR = 0.08, 95% CI 0.02 to 0.35). The associations were diminished after adjustment for GORD symptoms. The H pylori status was not an independent risk factor for Barrett's oesophagus compared with the GORD controls.
Helicobacter pylori infection and CagA+ status were inversely associated with a new diagnosis of Barrett's oesophagus. The findings are consistent with the hypothesis that H pylori colonisation protects against Barrett's oesophagus and that the association may be at least partially mediated through GORD.
幽门螺杆菌在胃内定植被认为是食管腺癌的一个保护因素,但其作用位点尚不清楚。本研究评估了幽门螺杆菌与巴雷特食管(Barrett's oesophagus)的关联,巴雷特食管是一种化生改变,可能是食管腺癌致癌过程中的早期事件。
在北加利福尼亚永久医疗集团(Kaiser Permanente)进行了一项病例对照研究,该集团是一个大型医疗服务机构。新诊断为巴雷特食管的患者(病例组)与无巴雷特食管的胃食管反流病(GORD)患者及人群对照组进行匹配。受试者完成了直接的面对面访谈以及幽门螺杆菌及其CagA(细胞毒素相关基因产物A)蛋白的抗体检测。
获取了318例巴雷特食管病例、312例GORD患者和299名人群对照组的血清学数据。与人群对照组相比,巴雷特食管患者感染幽门螺杆菌的抗体阳性率显著降低(比值比[OR]=0.42,95%可信区间[CI]为0.26至0.70);在体重指数较低(BMI<25,OR=0.03,95%CI为0.00至0.20)和感染CagA+菌株的患者中,这种负相关更强(OR=0.08,95%CI为0.02至0.35)。调整GORD症状后,这种关联减弱。与GORD对照组相比,幽门螺杆菌感染状态并非巴雷特食管的独立危险因素。
幽门螺杆菌感染及CagA+状态与新诊断的巴雷特食管呈负相关。这些发现与幽门螺杆菌定植可预防巴雷特食管的假说一致,且这种关联可能至少部分通过GORD介导。